The effect of the UPR and NMD mechanisms on the response to readthrough treatments von Oren, Y.S, Geiger, T, Mann, M, Kerem, B

Volltext

EPS4.03 ASOs reducing MUC5AC or MUC5B as a therapeutic approach for CF and other muco-obstructive diseases von Ozeri Galai, E., Oren, Y.S., Stampfer, C.D., Ba’al-Tzdaka, R.M., Blinder, T., Mordechai, T., Dahan, S., Kerem, B., Hart, G.

Volltext

WS05.04 SPL84 efficient and durable effect, restoring 3849 +10 kb C-to-T mutated CFTR, when treated through the apical side of primary HBE cells von Galai, E. Ozeri, Oren, Y.S., Cheng, Y., Chin, J., Stampfer, C.D., Coote, K., Mense, M., Kerem, B.

Volltext

P029 Antisense oligonucleotide-based drug development for cystic fibrosis patients carrying the 2789+5 G-to-A splicing mutation von Oren, Y.S., Barchad, O. Avizur, Galai, E. Ozeri, Elgrabli, R., Mordechai, T., Blinder, T., Stanleigh, N., Kerem, E., Kerem, B.

Volltext

P028 Antisense oligonucleotide splicing modulation as a novel cystic fibrosis (CF) therapeutic approach for the W1282X nonsense mutation von Barchad, O. Avizur, Oren, Y.S., Galai, E. Ozeri, Elgrabli, R., Schirelman, M.R., Blinder, T., Stampfer, C.D., Ordan, M., Laselvab, O., Cymberknoh, M. Cohen, Kerem, E., Bear, C.E., Kerem, B.

Volltext

Flap Reconstruction of Perineal Defects after Pelvic Exenteration: A Systematic Description of Four Choices of Surgical Reconstruction Methods von Witte, Donna Y. S., van Ramshorst, Gabrielle H., Lapid, Oren, Bouman, Mark-Bram, Tuynman, Jurriaan B.

Volltext